Napredna pretraga

Pregled bibliografske jedinice broj: 648433

Heterogeneity of manufacturers’ declarations for lipemia interference – urgent call for standardization


Nikolac, Nora; Šimundić, Ana-Maria; Mikša, Manuela; Lima-Oliveira, Gabriel; Salvagno, Gian Luca; Caruso, Beatrice; Guidi, Gian Cesare
Heterogeneity of manufacturers’ declarations for lipemia interference – urgent call for standardization // Clinica chimica acta, 426 (2013), 33-40 doi:10.1016/j.cca.2013.08.015 (međunarodna recenzija, članak, znanstveni)


Naslov
Heterogeneity of manufacturers’ declarations for lipemia interference – urgent call for standardization

Autori
Nikolac, Nora ; Šimundić, Ana-Maria ; Mikša, Manuela ; Lima-Oliveira, Gabriel ; Salvagno, Gian Luca ; Caruso, Beatrice ; Guidi, Gian Cesare

Izvornik
Clinica chimica acta (0009-8981) 426 (2013); 33-40

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Preanalytical error; interferences; lipemia; quality specifications; bias

Sažetak
Introduction: Due to the budget limitations, laboratories mostly rely on manufacturers’ information about the influence of interfering substances on laboratory results. However, some manufacturers do not follow recommended procedures for testing interferences (CLSI standard) and there is a great variability in the presentation of data regarding lipemia interference. Materials and methods: We aimed to verify manufacturers’ specifications for lipemia interference for clinical chemistry reagents provided by Beckman Coulter, Roche and Siemens. Bias was determined using the Intralipid® simulated lipemic samples. Furthermore, we aimed to compare obtained data with manufacturers’ claims and desirable specification for imprecision derived from biological variation. Results: i) manufacturers’ declarations were not confirmed for all three manufacturers ; ii) the magnitude and direction of the effect of lipemia on laboratory results differs substantially between the three tested analytical systems ; and iii) manufacturers are using arbitrary limits in declaring the expected effect of interference on laboratory results. Conclusions: There is an urgent need to standardize the way manufacturers test and report their data on the lipemia interference. We propose that, instead of arbitrary limits, manufacturers use evidence based quality specifications for assessing the allowable biases. Moreover, laboratories should be aware of the possible lack of replicability of manufacturers’ declarations.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Ana-Maria Šimundić, )

Ustanove
KBC "Sestre Milosrdnice"

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati